Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

Guochun Jiang, Erica A. Mendes, Philip Keiser, Daniel P. Wong, Yuyang Tang, Ivy Cai, Anne Fenton, Gregory P. Melcher, James E K Hildreth, George R. Thompson, Joseph K. Wong, Satya Dandekar

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Although anti-retroviral therapy (ART) is highly effective in suppressing HIV replication, it fails to eradicate the virus from HIV-infected individuals. Stable latent HIV reservoirs are rapidly established early after HIV infection. Therefore, effective strategies for eradication of the HIV reservoirs are urgently needed. We report that ingenol-3-angelate (PEP005), the only active component in a previously FDA approved drug (PICATO) for the topical treatment of precancerous actinic keratosis, can effectively reactivate latent HIV in vitro and ex vivo with relatively low cellular toxicity. Biochemical analysis showed that PEP005 reactivated latent HIV through the induction of the pS643/S676-PKCδ/θ-IκBα/ε-NF-κB signaling pathway. Importantly, PEP005 alone was sufficient to induce expression of fully elongated and processed HIV RNAs in primary CD4+ T cells from HIV infected individuals receiving suppressive ART. Furthermore, PEP005 and the P-TEFb agonist, JQ1, exhibited synergism in reactivation of latent HIV with a combined effect that is 7.5-fold higher than the effect of PEP005 alone. Conversely, PEP005 suppressed HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors. This anti-cancer compound is a potential candidate for advancing HIV eradication strategies.

Original languageEnglish (US)
Article numbere1005066
JournalPLoS Pathogens
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Fingerprint

NF-kappa B
HIV
HIV Infections
Positive Transcriptional Elongation Factor B
HIV Receptors
3-ingenyl angelate
Actinic Keratosis
T-Lymphocytes
RNA
Viruses

ASJC Scopus subject areas

  • Microbiology
  • Parasitology
  • Virology
  • Immunology
  • Genetics
  • Molecular Biology

Cite this

Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. / Jiang, Guochun; Mendes, Erica A.; Keiser, Philip; Wong, Daniel P.; Tang, Yuyang; Cai, Ivy; Fenton, Anne; Melcher, Gregory P.; Hildreth, James E K; Thompson, George R.; Wong, Joseph K.; Dandekar, Satya.

In: PLoS Pathogens, Vol. 11, No. 7, e1005066, 01.07.2015.

Research output: Contribution to journalArticle

Jiang, G, Mendes, EA, Keiser, P, Wong, DP, Tang, Y, Cai, I, Fenton, A, Melcher, GP, Hildreth, JEK, Thompson, GR, Wong, JK & Dandekar, S 2015, 'Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation', PLoS Pathogens, vol. 11, no. 7, e1005066. https://doi.org/10.1371/journal.ppat.1005066
Jiang, Guochun ; Mendes, Erica A. ; Keiser, Philip ; Wong, Daniel P. ; Tang, Yuyang ; Cai, Ivy ; Fenton, Anne ; Melcher, Gregory P. ; Hildreth, James E K ; Thompson, George R. ; Wong, Joseph K. ; Dandekar, Satya. / Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. In: PLoS Pathogens. 2015 ; Vol. 11, No. 7.
@article{80169d5f7ba144baa04e882428856d35,
title = "Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation",
abstract = "Although anti-retroviral therapy (ART) is highly effective in suppressing HIV replication, it fails to eradicate the virus from HIV-infected individuals. Stable latent HIV reservoirs are rapidly established early after HIV infection. Therefore, effective strategies for eradication of the HIV reservoirs are urgently needed. We report that ingenol-3-angelate (PEP005), the only active component in a previously FDA approved drug (PICATO) for the topical treatment of precancerous actinic keratosis, can effectively reactivate latent HIV in vitro and ex vivo with relatively low cellular toxicity. Biochemical analysis showed that PEP005 reactivated latent HIV through the induction of the pS643/S676-PKCδ/θ-IκBα/ε-NF-κB signaling pathway. Importantly, PEP005 alone was sufficient to induce expression of fully elongated and processed HIV RNAs in primary CD4+ T cells from HIV infected individuals receiving suppressive ART. Furthermore, PEP005 and the P-TEFb agonist, JQ1, exhibited synergism in reactivation of latent HIV with a combined effect that is 7.5-fold higher than the effect of PEP005 alone. Conversely, PEP005 suppressed HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors. This anti-cancer compound is a potential candidate for advancing HIV eradication strategies.",
author = "Guochun Jiang and Mendes, {Erica A.} and Philip Keiser and Wong, {Daniel P.} and Yuyang Tang and Ivy Cai and Anne Fenton and Melcher, {Gregory P.} and Hildreth, {James E K} and Thompson, {George R.} and Wong, {Joseph K.} and Satya Dandekar",
year = "2015",
month = "7",
day = "1",
doi = "10.1371/journal.ppat.1005066",
language = "English (US)",
volume = "11",
journal = "PLoS Pathogens",
issn = "1553-7366",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation

AU - Jiang, Guochun

AU - Mendes, Erica A.

AU - Keiser, Philip

AU - Wong, Daniel P.

AU - Tang, Yuyang

AU - Cai, Ivy

AU - Fenton, Anne

AU - Melcher, Gregory P.

AU - Hildreth, James E K

AU - Thompson, George R.

AU - Wong, Joseph K.

AU - Dandekar, Satya

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Although anti-retroviral therapy (ART) is highly effective in suppressing HIV replication, it fails to eradicate the virus from HIV-infected individuals. Stable latent HIV reservoirs are rapidly established early after HIV infection. Therefore, effective strategies for eradication of the HIV reservoirs are urgently needed. We report that ingenol-3-angelate (PEP005), the only active component in a previously FDA approved drug (PICATO) for the topical treatment of precancerous actinic keratosis, can effectively reactivate latent HIV in vitro and ex vivo with relatively low cellular toxicity. Biochemical analysis showed that PEP005 reactivated latent HIV through the induction of the pS643/S676-PKCδ/θ-IκBα/ε-NF-κB signaling pathway. Importantly, PEP005 alone was sufficient to induce expression of fully elongated and processed HIV RNAs in primary CD4+ T cells from HIV infected individuals receiving suppressive ART. Furthermore, PEP005 and the P-TEFb agonist, JQ1, exhibited synergism in reactivation of latent HIV with a combined effect that is 7.5-fold higher than the effect of PEP005 alone. Conversely, PEP005 suppressed HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors. This anti-cancer compound is a potential candidate for advancing HIV eradication strategies.

AB - Although anti-retroviral therapy (ART) is highly effective in suppressing HIV replication, it fails to eradicate the virus from HIV-infected individuals. Stable latent HIV reservoirs are rapidly established early after HIV infection. Therefore, effective strategies for eradication of the HIV reservoirs are urgently needed. We report that ingenol-3-angelate (PEP005), the only active component in a previously FDA approved drug (PICATO) for the topical treatment of precancerous actinic keratosis, can effectively reactivate latent HIV in vitro and ex vivo with relatively low cellular toxicity. Biochemical analysis showed that PEP005 reactivated latent HIV through the induction of the pS643/S676-PKCδ/θ-IκBα/ε-NF-κB signaling pathway. Importantly, PEP005 alone was sufficient to induce expression of fully elongated and processed HIV RNAs in primary CD4+ T cells from HIV infected individuals receiving suppressive ART. Furthermore, PEP005 and the P-TEFb agonist, JQ1, exhibited synergism in reactivation of latent HIV with a combined effect that is 7.5-fold higher than the effect of PEP005 alone. Conversely, PEP005 suppressed HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors. This anti-cancer compound is a potential candidate for advancing HIV eradication strategies.

UR - http://www.scopus.com/inward/record.url?scp=84938767578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938767578&partnerID=8YFLogxK

U2 - 10.1371/journal.ppat.1005066

DO - 10.1371/journal.ppat.1005066

M3 - Article

C2 - 26225771

AN - SCOPUS:84938767578

VL - 11

JO - PLoS Pathogens

JF - PLoS Pathogens

SN - 1553-7366

IS - 7

M1 - e1005066

ER -